Introduction: Beyond the Headline Number Eli Lilly announced a staggering 54% revenue growth to $17.60 billion in its third quarter of 2025, a figure largely driven by the blockbuster drugs Mounjaro and Zepbound . However, behind this headline number lies a more complex and fascinating story about the company's aggressive strategy on pricing, manufacturing, and future innovation. Our analysis of their latest financial report reveals four key takeaways that show what's really driving the company forward. 1. The Sheer Scale of the 'Incretin' Boom The massive growth is overwhelmingly powered by just two drugs from what CEO David A. Ricks calls the company's " incretin portfolio ." In Q3 2025, Mounjaro's revenue soared to $6.52 billion, a 109% year-over-year increase, while Zepbound's revenue hit $3.59 billion, a 185% increase. Combined, these two products brought in $10.11 billion for the quarter, accounting for approximately 57% of the company...